We’re pleased to announce that BASE Rx, a Sanger Institute spin-out looking to discover new cancer therapies, has been selected for the 2026 Accelerate@Babraham pre-seed programme. 👇
https://www.sanger.ac.uk/news_item/sanger-spin-out-secures-spot-on-game-changing-accelerator-programme/
BASE Rx joins company support programme, Accelerate@Babraham, designed to help start-ups navigate the life science sector.
